News | November 14, 2022
Chemcon Q2 FY23 revenue down 5.4%; Profit down 46.6%
Q2 FY23 business performance has been slow primarily due to lower volume offtake from pharmaceutical manufacturers
Q2 FY23 business performance has been slow primarily due to lower volume offtake from pharmaceutical manufacturers
The drug will be manufactured at the group’s formulation manufacturing facility at Ahmedabad SEZ, India
Pantoprazole Sodium Sesquihydrate are proton pump inhibitors used in drugs to suppress the gastric acid secretion
Revenue is up 23% whereas Profit After Tax expands 29% for the company
Ketorolac Tromethamine is advised for the short-term management of moderately severe acute pain in adult patients
The laboratory is equipped to perform high-volume diagnostic testing services
This is the first injectable product approval from our General Sterile Facility (F-3) which was inspected in August, 2022.
The expansion program includes investments in France and the U.S., adding an additional 23,000+ m² of manufacturing footprint.
The company is committed to addressing the observations at the earliest, and gaining approval for injectable manufacturing for the US
The observation is procedural in nature and the company will address the observation within stipulated timelines.
Subscribe To Our Newsletter & Stay Updated
